점안 안약 전달 기술 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)
Ocular Drug Delivery Technology Market (Technology: Topical, Ocular Insert, Iontophoresis, Intraocular Implant, In Situ Gel & Punctal Plug, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
상품코드:1487587
리서치사:Transparency Market Research
발행일:2024년 04월
페이지 정보:영문 214 Pages
라이선스 & 가격 (부가세 별도)
한글목차
점안 안약 전달 기술 시장- 조사 범위
TMR의 조사 보고서 "세계 점안 안약 전달 기술 시장"은 2024년부터 2034년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사하여 2024년을 기준 연도로, 2034년을 예측 연도로 삼았습니다. 으로 2018년부터 2034년까지 세계 점안 안약 전달 기술 시장의 수익을 제공합니다. 또한 2024년부터 2034년까지 세계 점안 안약 전달 기술 시장의 연평균 복합 성장률(CAGR%)을 제공합니다.
이 보고서는 1차 조사에서 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하고, 2차 조사에서 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 등을 참조하여 경구용 약물 전달 기술 시장을 이해하고자 했습니다. 기술 시장을 이해했습니다.
시장 현황
2023년 시장 규모
163억 달러
2034년 시장 가치
302억 달러
CAGR
5.7%
이 보고서는 세계 경구용 약물 전달 기술 시장 경쟁 구도를 심층적으로 분석합니다. 세계 점안 안약 전달 기술 시장에서 활동하는 주요 업체를 식별하고, 각 업체는 다양한 속성으로 프로파일링됩니다. 기업 개요, 재무 상태, 최근 동향 및 SWOT는 이 보고서에서 다루는 세계 경안 약물 전달 기술 시장 기업의 속성입니다.
목차
제1장 서문
제2장 조사의 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
서론
시장 개요
시장 역학
세계 시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
파이프라인 분석
주요 제품/브랜드 분석
주요 M&A
COVID-19 팬데믹의 산업에 대한 영향
제6장 세계 시장 분석과 예측 : 기술별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 기술별, 2020-2034
국소용
안용 인서트
탈취성
비소모성
이온트포레시스
안내 임플란트
생분해성
비생분해성
In Situ Gel & Punctal Plug
기타
시장의 매력 : 기술별
제7장 세계 시장 분석과 예측 : 제제 유형별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 제제 유형별, 2020년-2034년
용액
현탁액
에멀전
리포솜 및 나노입자
연고
시장의 매력 : 제제 유형별
제8장 세계 시장 분석과 예측 : 질환 유형별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 질환 유형별, 2020-2034년
녹내장
황반변성
당뇨병 망막증
백내장
당뇨병성 황반부종
안구건조증
기타
시장의 매력 : 질환 유형별
제9장 세계 시장 분석과 예측 : 최종사용자별
서론과 정의
주요 조사 결과/발전
시장 매출 예측 : 최종사용자별, 2020년-2034년
병원
외래수술센터(ASC)
안과 클리닉
재택치료
시장의 매력 : 최종사용자별
제10장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별, 2020-2034
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 : 지역별
제11장 북미 시장 분석과 예측
제12장 유럽 시장 분석과 예측
제13장 아시아태평양 시장 분석과 예측
제14장 라틴아메리카 시장 분석과 전망
제15장 중동 및 아프리카 시장 분석과 예측
제16장 경쟁 구도
시장 경쟁 매트릭스(기업 Tier별, 기업 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
Ocular Therapeutix, Inc.
Alimera Sciences Inc.
Allergan(an AbbVie company)
Bausch Health Companies Inc.
EyeGate Pharmaceuticals, Inc.
Envisia Therapeutics Inc.
Clearside Biomedical, Inc.
Graybug Vision, Inc.
Santen Pharmaceutical Co., Ltd.
Taiwan Liposome Company, Ltd.
LSH
영문 목차
영문목차
Ocular Drug Delivery Technology Market - Scope of Report
TMR's report on the global ocular drug delivery technology market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global ocular drug delivery technology market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ocular drug delivery technology market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the ocular drug delivery technology market.
Market Snapshot
Market Value in 2023
US$ 16.3 Bn
Market Value in 2034
US$ 30.2 Bn
CAGR
5.7%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global ocular drug delivery technology market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global ocular drug delivery technology market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global ocular drug delivery technology market.
The report delves into the competitive landscape of the global ocular drug delivery technology market. Key players operating in the global ocular drug delivery technology market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global ocular drug delivery technology market profiled in this report.
Key Questions Answered in Global ocular drug delivery technology Market Report:
What is the sales/revenue generated by ocular drug delivery technology across all regions during the forecast period?
What are the opportunities in the global ocular drug delivery technology market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Ocular Drug Delivery Technology Market - Research Objectives and Research Approach
The comprehensive report on the global ocular drug delivery technology market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global ocular drug delivery technology market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global ocular drug delivery technology market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Ocular Drug Delivery Technology Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Ocular Drug Delivery Technology Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Ocular Drug Delivery Technology Market Analysis and Forecast, by Technology
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Technology, 2020-2034
6.3.1. Topical
6.3.2. Ocular Insert
6.3.2.1. Erodible
6.3.2.2. Non-erodible
6.3.3. Iontophoresis
6.3.4. Intraocular Implant
6.3.4.1. Biodegradable
6.3.4.2. Non-biodegradable
6.3.5. In Situ Gel & Punctal Plug
6.3.6. Others
6.4. Market Attractiveness, by Technology
7. Global Ocular Drug Delivery Technology Market Analysis and Forecast, by Formulation Type
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Formulation Type, 2020-2034
7.3.1. Solution
7.3.2. Suspension
7.3.3. Emulsion
7.3.4. Liposome & Nanoparticle
7.3.5. Ointment
7.4. Market Attractiveness, by Formulation Type
8. Global Ocular Drug Delivery Technology Market Analysis and Forecast, by Disease Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Disease Type, 2020-2034
8.3.1. Glaucoma
8.3.2. Macular Degeneration
8.3.3. Diabetic Retinopathy
8.3.4. Cataract
8.3.5. Diabetic Macular Edema
8.3.6. Dry Eye Syndrome
8.3.7. Others
8.4. Market Attractiveness, by Disease Type
9. Global Ocular Drug Delivery Technology Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Ophthalmic Clinics
9.3.4. Homecare Settings
9.4. Market Attractiveness, by End-user
10. Global Ocular Drug Delivery Technology Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Ocular Drug Delivery Technology Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Technology, 2020-2034
11.2.1. Topical
11.2.2. Ocular Insert
11.2.2.1. Erodible
11.2.2.2. Non-erodible
11.2.3. Iontophoresis
11.2.4. Intraocular Implant
11.2.4.1. Biodegradable
11.2.4.2. Non-biodegradable
11.2.5. In Situ Gel & Punctal Plug
11.2.6. Others
11.3. Market Attractiveness, by Technology
11.4. Market Value Forecast, by Formulation Type, 2020-2034
11.4.1. Solution
11.4.2. Suspension
11.4.3. Emulsion
11.4.4. Liposome & Nanoparticle
11.4.5. Ointment
11.5. Market Attractiveness, by Formulation Type
11.6. Market Value Forecast, by Disease Type, 2020-2034
11.6.1. Glaucoma
11.6.2. Macular Degeneration
11.6.3. Diabetic Retinopathy
11.6.4. Cataract
11.6.5. Diabetic Macular Edema
11.6.6. Dry Eye Syndrome
11.6.7. Others
11.7. Market Attractiveness, by Disease Type
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospitals
11.8.2. Ambulatory Surgical Centers
11.8.3. Ophthalmic Clinics
11.8.4. Homecare Settings
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Technology
11.11.2. By Formulation Type
11.11.3. By Disease Type
11.11.4. By End-user
11.11.5. By Country
12. Europe Ocular Drug Delivery Technology Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Technology, 2020-2034
12.2.1. Topical
12.2.2. Ocular Insert
12.2.2.1. Erodible
12.2.2.2. Non-erodible
12.2.3. Iontophoresis
12.2.4. Intraocular Implant
12.2.4.1. Biodegradable
12.2.4.2. Non-biodegradable
12.2.5. In Situ Gel & Punctal Plug
12.2.6. Others
12.3. Market Attractiveness, by Technology
12.4. Market Value Forecast, by Formulation Type, 2020-2034
12.4.1. Solution
12.4.2. Suspension
12.4.3. Emulsion
12.4.4. Liposome & Nanoparticle
12.4.5. Ointment
12.5. Market Attractiveness, by Formulation Type
12.6. Market Value Forecast, by Disease Type, 2020-2034
12.6.1. Glaucoma
12.6.2. Macular Degeneration
12.6.3. Diabetic Retinopathy
12.6.4. Cataract
12.6.5. Diabetic Macular Edema
12.6.6. Dry Eye Syndrome
12.6.7. Others
12.7. Market Attractiveness, by Disease Type
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospitals
12.8.2. Ambulatory Surgical Centers
12.8.3. Ophthalmic Clinics
12.8.4. Homecare Settings
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Technology
12.11.2. By Formulation Type
12.11.3. By Disease Type
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Ocular Drug Delivery Technology Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Technology, 2020-2034
13.2.1. Topical
13.2.2. Ocular Insert
13.2.2.1. Erodible
13.2.2.2. Non-erodible
13.2.3. Iontophoresis
13.2.4. Intraocular Implant
13.2.4.1. Biodegradable
13.2.4.2. Non-biodegradable
13.2.5. In Situ Gel & Punctal Plug
13.2.6. Others
13.3. Market Attractiveness, by Technology
13.4. Market Value Forecast, by Formulation Type, 2020-2034
13.4.1. Solution
13.4.2. Suspension
13.4.3. Emulsion
13.4.4. Liposome & Nanoparticle
13.4.5. Ointment
13.5. Market Attractiveness, by Formulation Type
13.6. Market Value Forecast, by Disease Type, 2020-2034
13.6.1. Glaucoma
13.6.2. Macular Degeneration
13.6.3. Diabetic Retinopathy
13.6.4. Cataract
13.6.5. Diabetic Macular Edema
13.6.6. Dry Eye Syndrome
13.6.7. Others
13.7. Market Attractiveness, by Disease Type
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Hospitals
13.8.2. Ambulatory Surgical Centers
13.8.3. Ophthalmic Clinics
13.8.4. Homecare Settings
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Technology
13.11.2. By Formulation Type
13.11.3. By Disease Type
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Ocular Drug Delivery Technology Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Technology, 2020-2034
14.2.1. Topical
14.2.2. Ocular Insert
14.2.2.1. Erodible
14.2.2.2. Non-erodible
14.2.3. Iontophoresis
14.2.4. Intraocular Implant
14.2.4.1. Biodegradable
14.2.4.2. Non-biodegradable
14.2.5. In Situ Gel & Punctal Plug
14.2.6. Others
14.3. Market Attractiveness, by Technology
14.4. Market Value Forecast, by Formulation Type, 2020-2034
14.4.1. Solution
14.4.2. Suspension
14.4.3. Emulsion
14.4.4. Liposome & Nanoparticle
14.4.5. Ointment
14.5. Market Attractiveness, by Formulation Type
14.6. Market Value Forecast, by Disease Type, 2020-2034
14.6.1. Glaucoma
14.6.2. Macular Degeneration
14.6.3. Diabetic Retinopathy
14.6.4. Cataract
14.6.5. Diabetic Macular Edema
14.6.6. Dry Eye Syndrome
14.6.7. Others
14.7. Market Attractiveness, by Disease Type
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospitals
14.8.2. Ambulatory Surgical Centers
14.8.3. Ophthalmic Clinics
14.8.4. Homecare Settings
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Technology
14.11.2. By Formulation Type
14.11.3. By Disease Type
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Ocular Drug Delivery Technology Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Technology, 2020-2034
15.2.1. Topical
15.2.2. Ocular Insert
15.2.2.1. Erodible
15.2.2.2. Non-erodible
15.2.3. Iontophoresis
15.2.4. Intraocular Implant
15.2.4.1. Biodegradable
15.2.4.2. Non-biodegradable
15.2.5. In Situ Gel & Punctal Plug
15.2.6. Others
15.3. Market Attractiveness, by Technology
15.4. Market Value Forecast, by Formulation Type, 2020-2034
15.4.1. Solution
15.4.2. Suspension
15.4.3. Emulsion
15.4.4. Liposome & Nanoparticle
15.4.5. Ointment
15.5. Market Attractiveness, by Formulation Type
15.6. Market Value Forecast, by Disease Type, 2020-2034
15.6.1. Glaucoma
15.6.2. Macular Degeneration
15.6.3. Diabetic Retinopathy
15.6.4. Cataract
15.6.5. Diabetic Macular Edema
15.6.6. Dry Eye Syndrome
15.6.7. Others
15.7. Market Attractiveness, by Disease Type
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospitals
15.8.2. Ambulatory Surgical Centers
15.8.3. Ophthalmic Clinics
15.8.4. Homecare Settings
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Technology
15.11.2. By Formulation Type
15.11.3. By Disease Type
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Ocular Therapeutix, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Alimera Sciences Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Allergan (an AbbVie company)
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Bausch Health Companies Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. EyeGate Pharmaceuticals, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Envisia Therapeutics Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Clearside Biomedical, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Graybug Vision, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Santen Pharmaceutical Co., Ltd.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Taiwan Liposome Company, Ltd.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
